Idexx Laboratories reports Q3 EPS $2.53 with items, consensus $2.37

Reports Q3 revenue $916M, consensus $926.76M. Q3 EPS includes 4c per share in tax benefits from share-based compensation and 1c per share negative impact from currency changes. “Strong execution by IDEXX teams and sustained interest in adopting IDEXX’s differentiated multi-modality testing and workflow solutions helped deliver solid organic revenue gains and strong financial results in the Q3,” said Jay Mazelsky, President and CEO. “Busy veterinarians appreciate that they must very often first test before they can determine the most optimal treatment course, which drives the medical services activity in their practice. They also want these testing solutions to seamlessly connect to a modern cloud-based PIMS, and have shown an increased appetite to invest in software that supports higher staff productivity and client communications. IDEXX remains very well positioned to address these needs while driving development of the companion animal diagnostics sector through relevant innovation and commercial engagement.”